C4 Therapeutics has been granted a patent for Degronimers, compounds with carbon-linked E3 Ubiquitin Ligase targeting moieties for in vivo protein degradation. The invention includes methods of use, compositions, and preparation. GlobalData’s report on C4 Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on C4 Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. C4 Therapeutics's grant share as of May 2024 was 5%. Grant share is based on the ratio of number of grants to total number of patents.
Degronimers for in vivo protein degradation
The granted patent (Publication Number: US11992531B2) discloses a compound of Formula with various specific configurations and substitutions, targeting proteins such as estrogen receptor, androgen receptor, AKT1, AXL, ABL, Bcl-2, and many others. The compound can be used in pharmaceutical compositions with acceptable excipients for treating disorders mediated by the targeted proteins, including tumors and cancer.
The patent also covers a method for treating patients with disorders mediated by the targeted proteins by administering the compound or its pharmaceutically acceptable salt in a carrier. The targeted proteins range from histone deacetylase, heat shock protein, and HIV integrase to PPAR-gamma, VEGF receptor, and mTORC1. This innovative approach provides a wide range of potential applications in the treatment of various diseases and conditions associated with these specific proteins, offering a promising avenue for therapeutic interventions in cancer and other related disorders.
To know more about GlobalData’s detailed insights on C4 Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
